New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
11:50 EDTAZN, CGIXCancer Genetics rises after selection by AstraZeneca unit
Shares of Cancer Genetics (CGIX), an early-stage, diagnostic company that focuses on developing and commercializing genomic tests and services focused on improving cancer care, are higher this morning after the company announced a partnership with AstraZeneca (AZN). WHAT'S NEW: AstraZeneca CAMCAR, a division of the pharmaceutical giant that serves Central American and Caribbean countries, has selected Cancer Genetics to provide diagnostic testing based on biomarkers for cancer. CGI will perform complex testing for diagnosis and prognosis of cancer patients in Central America and the Caribbean. Under the terms of the agreement, CGI will be working closely with AZ-CAMCAR on exploring opportunities to expand into additional geographic territories, more cancer categories and into select oncology trials. This partnership will focus on multiple cancer categories beginning with lung cancer, as the Pan American Health Organization, or PAHO, expects cases the number of new cases and deaths from lung cancer to double in Latin America by 2030. WHAT'S NOTABLE: Cancer Genetics Chief Executive Officer Panna Sharma commented, "We believe our ability to provide accurate, state-of-the-art biomarker-based testing was a key factor in AstraZeneca’s decision to partner with us, and serves as a testament to the growing global awareness of the value of our brand. We are committed to positively impacting cancer care globally, and this relationship serves as another major milestone in fulfilling that mission." PRICE ACTION: Cancer Genetics is trading up 38c, or 3.4%, to $11.58 in late-morning trading.
News For CGIX;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 2, 2015
08:03 EDTCGIXCancer Genetics wins Bankruptcy court approval to buy Response Genetics
Subscribe for More Information
October 1, 2015
07:31 EDTAZNLeerink to hold a roundtable
Subscribe for More Information
September 30, 2015
08:02 EDTAZNAstraZeneca says SYMBICORT results published in journal
Subscribe for More Information
September 29, 2015
08:07 EDTAZNAstraZeneca says Brilinta 60-mg tablets now available in U.S. pharmacies
Subscribe for More Information
September 28, 2015
07:52 EDTAZNIIR Holdings to hold a conference
Subscribe for More Information
September 25, 2015
07:22 EDTAZNEuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
September 22, 2015
08:02 EDTAZNAstraZeneca to present 33 abstracts from respiratory disease portfolio at ERS
Subscribe for More Information
07:43 EDTAZNDrug stocks could be hurt by focus on pricing, says Oppenheimer
Subscribe for More Information
07:17 EDTAZNAstraZeneca eyes crowd sourcing for better cancer drug cocktails, Reuters says
AstraZeneca's decision release preclinical data from over 50 of its medicines is "unprecedented" in scale and will speed up the hunt for tumor-fighting drug combinations, Reuters says. The company is aiming for a crowd sourcing initiative to help mix the future's cancer drug cocktails, the report says. Reference Link
06:19 EDTAZNClinton to roll out plan to rein in prescription drug costs, USA Today reports
Subscribe for More Information
September 21, 2015
14:28 EDTAZNTuring CEO says will not change Daraprim price despite criticism
Subscribe for More Information
11:24 EDTAZNHillary Clinton vows to take on 'outrageous' specialty drug pricing
Hillary Clinton, on the heels of a Wall Street Journal report detailing Turing Pharmaceuticals' price hike to $750 from $13.50 per pill of a drug called Daraprim which treats a life-threatening parasitic infection, vowed to lay out a plan tomorrow to take on what she calls "price gouging" of specialty drugs. The presidential nominee stated in a tweet, "Price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on." The iShares Nasdaq Biotechnology Index (IBB) moved lower following Clinton's tweet.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use